

Genetic Networks of Alzheimer's Disease, Aging and Longevity in Humans

Timothy Balmorez,¹ Amy Sakazaki,¹ and Shin Murakami*

Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592.

¹, Equal contribution

*, Corresponding author, Shin Murakami, PHD, FGSA
1310 Club Dr, Mare Island, Vallejo CA 94592
E-mail: shin.murakami@tu.edu

Abstract

Human genomic analysis and genome-wide association studies (GWAS) have identified genes that are risk factors for early and late-onset Alzheimer's disease (AD genes). Although the genetics of aging and longevity has been extensively studied, previous studies have focused on a specific set of genes that have been shown to contribute to or to be a risk factor for AD. Thus, the connections among the genes involved in AD, aging, and longevity are not well understood. Here, we identified the genetic interaction networks (referred to as pathways) of aging and longevity within the context of AD, using a gene set enrichment analysis by Reactome that cross-references more than 100 bioinformatic databases to allow interpretation of the biological functions of gene sets through a wide variety of gene networks. We validated the pathways with a threshold of p -value $< 1.00E-05$, using the databases to extract lists of 356 AD genes, 307 aging-related (AR) genes, and 357 longevity genes. There was a broad range of biological pathways involved in AR and Longevity genes shared with AD genes. AR genes identified 261 pathways within the threshold of $p < 1.00E-05$, of which 26 pathways (10% of AR gene pathways) were further identified by overlapping genes among AD and AR genes. The overlapped pathways included Gene Expression ($p = 4.05E-11$) including ApoE, SOD2, TP53 and TGFB1 ($p = 2.84E-10$); Protein Metabolism and SUMOylation including E3 ligases and target proteins ($p = 1.08E-07$), ERBB4 signal transduction ($p = 2.69E-06$), Immune System including IL-3 and IL-13 ($p = 3.83E-06$), Programmed Cell Death ($p = 4.36E-06$) and platelet degranulation ($p = 8.16E-06$) among others. Longevity genes identified 49 pathways within the threshold, of which 12 pathways (24% of Longevity gene pathways) were further identified by overlapping genes among AD and Longevity genes. They include the immune system including IL-3 and IL-13 ($p = 7.64E-08$), plasma lipoprotein assembly, remodeling and clearance ($p < 4.02E-06$), metabolism of fat-soluble vitamins ($p = 1.96E-05$). Thus, this study provides shared genetic hallmarks of aging, longevity, and AD backed up by statistical significance. We discuss significant genes involved in these pathways, including TP53, FOXO, Sumoylation, IL4, IL6, APOE, and CEPT, and suggest that mapping the gene network pathways provide a useful basis for further medical research, education, and community outreach.

Introduction

Alzheimer's disease is the most frequent cause of dementia in which about 5.0 million people are living with AD in 2014 and the number is estimated to nearly triple by 2060 (Matthews et al.,

52 2018). The centers for disease control and prevention (CDC) states that the number of people
53 living with AD doubles every 5 years beyond age 65 (Accessed on January 2023;
54 <https://www.cdc.gov/aging/aginginfo/alzheimers.htm>). Aging and genetic variations are well-
55 known risks for AD. The genetic basis of AD has been characterized in the early onset of AD
56 (EOAD), including amyloid precursor protein (APP) (Goate et al., 1991), presenilin 1 (PSEN1)
57 (Sherrington et al., 1995), and presenilin 2 (PSEN2) (Rogaev et al., 1995), which account for
58 less than 1% of AD cases (Sherva and Kwall, 2022). The vast majority of genetic risk factors fall
59 into late-onset AD (LOAD). Additionally, the predictive contribution of each gene is modest for
60 LOAD (Harold et al., 2009). Thus, research on the profiles of AD risk factor genes (AD genes) is
61 expected to be effective. AD genes identified lipoprotein metabolism as a major hallmark of AD,
62 which is tightly linked to a major mortality risk, cardiovascular disease (Vahdati Nia et al., 2017;
63 Murakami and Lacayo, 2022). A component of lipoprotein metabolism includes ApoE isoforms
64 which are well-known as a risk factor for LOAD (Mooser et al., 2000) as well as associated with
65 longevity (Reviewed in Sebastiani et al., 2019). However, although there are genetic variants
66 associated with aging (i.e., pathophysiological changes with increasing age) and longevity (i.e.,
67 length of lifespan), genetic interconnections with AD are not yet fully understood (Christensen et
68 al., 2006; Vahdati Nia et al., 2017; Murakami and Lacayo, 2022). We reason that studying the
69 gene sets or profiles is an effective way to understand AD and its relationship with aging and
70 longevity. In this study, we chose a type of bioinformatic analysis using Reactome to elucidate
71 the underlying molecular pathways and mechanisms.

72
73 Reactome is an open-source bioinformatic database with two functions. Firstly, it is a knowledge
74 database of biological pathways manually curated and peer-reviewed, including twenty-seven
75 biological pathway groups: they are autophagy, cell cycle, cell-cell communication, cellular
76 responses to external stimuli, chromatin organization, circadian clock, developmental biology,
77 digestion and absorption, disease, among others (Jassal et al., 2020). The pathway, reaction,
78 and molecules pages extensively cross-reference to more than 100 bioinformatics resources,
79 including ChEBI small molecule databases, Ensembl and UniProt databases, NCBI Gene, the
80 UCSC Genome Browser, and PubMed. Secondly, it serves as a bioinformatic tool to perform
81 gene set enrichment analysis (GSEA) (Milacic et al., 2012; Fabregat et al., 2018). GSEA is a
82 computational method to identify and interpret biological functions of a gene set from genome-
83 wide profiles. It uses gene annotations (such as gene ontology (GO), disease ontology (DO),
84 and pathway annotations) and provides a ranked list of annotations with statistical significance
85 for validation of the ranked list (Subramanian et al. 2005).

86
87 Using the Reactome analysis, we investigated three types of human genes: AD genes, aging-
88 related (AR) genes, and Longevity genes. AD genes have been reported previously, which are
89 validated based on meta-analyses of human GWAS (genome-wide association) studies
90 (Bertram et al., 2007; Vahdati Nia et al., 2017; Murakami and Lacayo, 2022). Aging-related (AR)
91 genes in humans are a list of genes identified based on an extensive literature review, followed
92 by manually-curated annotation (de Magalhaes et al., 2009). The genes are from the meta-
93 analysis study of human gene-expression analysis as well as predicted based on the studies in
94 model systems, including the yeast, the nematode, the fruit fly, and the mouse (de Magalhaes et
95 al., 2009). The proteomic and genomic map of the AR gene list has been reported earlier (de
96 Magalhães and Toussaint, 2004). Longevity genes are the genes identified as gene variants
97 associated with longevity (Budovsky et al., 2013). Notable risk factors for Alzheimer's include
98 APOE, as well as genes associated with inflammation and the insulin/IGF-1 signaling pathway
99 (Willcox et al., 2008). However, although AD, aging, and longevity may be associated with each
100 other, there is a lack of genetic interaction maps that overview each of them. Thus, we
101 investigated the connections among the genes involved in AD, aging, and longevity.

102

103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153

Materials and Methods

Datasets

We used three sets of genes for our study: human Alzheimer’s Disease (AD) genes, Aging-Related (AR) genes, and Longevity genes. With these three gene sets, two additional gene sets were created by: (1) identifying the genes shared both by the AD genes and by the AR genes (AD-AR Overlap), and (2) identifying the genes shared both by AD genes and Longevity genes (AD-Longevity Overlap). Firstly, we utilized the AlzGene database (www.alzgene.org; last accessed May 2021) to extract a list of 680 identified human AD genes from GWAS and previous linkage studies (Bertram et al., 2007; Olgiati et al., 2011). Each gene from the database was linked to a number of positive or negative test results from each GWAS study, which were then used to validate the reliability of the data. Out of the 680 genes, 356 genes had positive results (AD genes) and 324 genes had negative results. Since the definite negative and positive results were not included in the database, we used the p -value from previous studies. If $p < 0.05$, we assumed the data was reliable and counted them as a positive result; studies with $p > 0.05$ were regarded as negative and were not included in our study. Research outcomes listed as trends or inconclusive were also not included in our study. Secondly, we utilized the GenAge database (www.genomics.senescence.info; last accessed May 2021), a benchmark database of 307 genes possibly related to human aging (AR). The genes were extensively reviewed for inclusion based on findings in model organisms put in the context of human biology plus genes directly related to aging in humans (Tacutu et al., 2018). Thirdly, we utilized the LongevityMap database (www.genomics.senescence.info/longevity/; last accessed December 2021), a database of 751 genes associated with human longevity (Budovsky et al., 2013). In the database, 394 genes were labeled “non-significant” and thus excluded from this study for analysis. The remaining 357 genes were labeled as “significant” (Longevity genes) and used in this study. Finally, the list of AD Genes was used to cross-reference the presence of any genes shared by the combinations of each gene sets (AD-AR overlap genes and AD-Longevity overlap genes). When comparing AD genes with AR genes, 41 overlappings (AD-AR overlap) genes were found. When comparing AD genes and Longevity genes, 43 overlappings (AD-Longevity overlap) genes were found.

Gene Ontology: Reactome Analysis

We used Reactome (www.reactome.org) to analyze the pathways involved in each gene set. The pathways with a threshold of $p < 10E-5$ were selected and used for this study. Reactome analysis was performed as described previously (Vahdati Nia et al., 2017; Murakami and Lacayo, 2022). Reactome FIViz was used to determine enrichment in the Functional Interaction (FI) network, the pathway enrichment of the genes of interest, followed by converting the results to interactomes. Statistics and false discovery rate (FDR) were calculated by the Reactome FIViz. We used Cytoscape ver. 3.8.2 (Java version: 11.0.6) to run the Reactome software plugin, Reactome FIViz app (Wu et al., 2014). The version of the pathway database was Reactome v76 (released on March 21, 2021; last accessed on May 26, 2021).

Results

Figure 1 summarises the overall analysis of the gene sets. We identified five gene sets as described in the method. They are (1) 356 positive AD genes; (2) 307 AR genes; (3) 357 Longevity genes; (4) 41 AD-AR overlap genes; and (5) 43 AD-Longevity overlap genes (Figure 1). We then perform a Reactome analysis of each gene set that generated biological pathways relevant to the gene set. The pathways were validated by using the threshold of $p < 10E-5$; in

154 other words, we excluded the pathways with a false discovery rate of more than 10E-3. In each
155 Table, we included the top ten results from each Reactome analysis to be included in our
156 results. We further identified specific Reactome groups from within the generalized groups.

157

158 **AD Genes**

159 The Reactome analysis of the AD genes identified 161 pathways. Of them, 53 pathways
160 showed $p < 1.0E-05$, which is roughly equivalent to the false discovery rate $< 1.0E-03$. The
161 significant pathways can be summarized into the following three general Reactome pathway
162 groups: Metabolism of RNA, Transport of Small molecules, and Immune System. The top 10
163 results are shown in Table 1.

164

165 The top hit for the enriched pathway analysis (of AD positive genes) was “tRNA processing in
166 the mitochondrion” (FDR = 1.01E-13; $p = 1.11E-16$), which was a sub-pathway topic under
167 “tRNA processing” (FDR = 1.09E-6; $p = 1.09E-8$), which was a sub-pathway topic under
168 “metabolism of RNA” in the hierarchy panel. “tRNA processing in the mitochondrion” involves 42
169 proteins and 19 of those proteins were found to be shared in our positively tested AD genes
170 (FDR = 1.01E-13; $p = 1.11E-16$). The second top hit was “Plasma lipoprotein assembly,
171 remodeling, and clearance” (FDR = 1.34E-1; $p = 4.44E-16$) from the “Transport of Small
172 Molecules” general pathway. The third-fourth top hit, “Interleukin-4 and Interleukin-13 signaling”
173 (FDR = 5.80E-10; $p = 2.57E-12$) is a part of the “Immune System” general pathway.

174

175 **AR Genes**

176 669 pathways were identified by the Reactome analysis of the 307 AR genes. Using the
177 threshold, we validated the pathways and selected 261 pathways using the threshold of $p <$
178 $1.0E-05$. The significant pathways identified by the AR genes fell into the following six general
179 Reactome pathway groups: Immune System, Signal Transduction, Metabolism of Proteins,
180 Gene Expression, Cellular Responses to External Stimuli, and DNA repair. The top ten results
181 are shown in Table 2.

182

183 The top hits for the enriched pathway analysis and their general pathways were the following:
184 Signaling by interleukins (Immune system), DNA Double-Strand Break Repair (DNA repair),
185 PIP3 activates AKT Signaling (Signal Transduction), FOXO-mediated transcription (Gene
186 Expression), cellular responses to stress (cellular responses to external stimuli), SUMO E3
187 ligases SUMOylate target proteins (Metabolism of Proteins), cellular senescence (cellular
188 responses to external stimuli), transcriptional regulation by TP53 (Gene Expression), and
189 SUMOylation (Protein Metabolism). All results had an FDR = 8.66E-15; $p = 1.11E-16$.

190

191 **Longevity Genes**

192 34 pathways were identified in the Reactome analysis of 357 Longevity genes. Of them, we
193 validated and selected 12 pathways that satisfied the threshold of $p < 1.0E-05$. The significant
194 pathways resulted in two general pathways: Signal Transduction and Gene Expression. The top
195 10 results are shown in Table 3. The top results in the enrichment pathway analysis were part of
196 the “Signal Transduction” general pathway. The Reactome pathway “MTOR signaling”, (FDR =
197 5.15E-14; $p = 1.11E-16$) is a sub-pathway topic under “intracellular signaling by second
198 messengers” (FDR = 5.39E-12, $p = 1.74E-14$). “MTOR signaling pathway” involves 41 proteins
199 and 19 of those proteins were found to be shared in our Longevity genes. “PIP3 activates AKT
200 signaling”, (FDR = 2.39E-11, $p = 1.03E-13$) is also a sub-pathway topic under the same
201 pathway. In the “Gene Expression” general pathway, the significant pathways were “RNA
202 Polymerase II Transcription” (FDR = 1.29E-09, $p = 1.04E-11$) and two sub-pathways – “TP53
203 Regulates Metabolic Genes” (FDR = 1.29E-09, $p = 1.11E-11$) and “FOXO-mediated
204 transcription” (FDR = 1.78E-09, $p = 1.73E-11$).

205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254

AD-AR overlap genes

41 AR genes (13% of the genes) overlapped with AD genes (AD-AR overlap genes) (Table 4). The Reactome analysis of the AD-AR overlaps genes 261 pathways. Of them, we validated and selected 24 pathways that satisfied the threshold of $p < 1.0E-05$. The pathways resulted in five general Reactome groups: Gene Expression, Metabolism of Proteins, Programmed Cell Death, Signal Transduction, and Immune System. The top ten results are shown in Table 5.

The top result for the enriched pathway analysis was “Generic Transcription Pathway” (FDR = $1.85E-08$; $p = 4.05E-11$), which was a sub-pathway topic under “RNA polymerase II transcription” (FDR $1.85E-08$; $p = 2.84E-10$), which was a sub-pathway topic under the “Gene Expression” general pathway. Within “Generic Transcription Pathway”, the analysis highlighted “nuclear receptor transcription pathway” (FDR = $9.705E-04$; $p = 4.85E-05$) and “TP53 regulates transcription of cell death genes” (FDR = $5.90E-04$; $p = 2.36E-05$). “Generic transcription pathway” involves 1,234 proteins and 22 of those proteins were found to be shared in AD-AR overlap genes (FDR = $1.85E-08$; $p = 4.05E-11$).

Pathways within the AD-AR overlap genes (Figures 2 and 3) for the “generic transcription pathway” included the following sub-pathways: “nuclear receptor transcription pathway” and “transcriptional regulation by TP53”. Under “SUMOylation” hit genes included the following sub-pathways: “SUMO E3 ligases SUMOylate target proteins”, “SUMOylation of intracellular receptors”, “SUMOylation of transcription factors”, and “SUMOylation of DNA damage response and repair proteins”.

AD-Longevity overlap genes

43 genes of Longevity genes (12% of the genes) overlapped with AD genes (Table 6). The Reactome analysis of AD-longevity overlap genes identified 34 pathways, of which 12 pathways were validated within the threshold of $p < 1.0E-05$. The 12 pathways were in the following 4 Reactome general pathways: Immune System, Plasma lipoprotein assembly, remodeling, and clearance, Metabolism of vitamins and cofactors, and Signal Transduction. The top 10 results are shown in Table 7.

The top result from the enriched pathway analysis is “Interleukin-4 and Interleukin-13 signaling” (FDR = $2.32E-05$; $p = 7.64E-08$) which is a sub-pathway of “signaling by Interleukins” (FDR $4.57E-04$; $p = 1.20E-05$) and part of the “Immune System” general pathway. Out of the 112 proteins found to be involved in the “Interleukin-4 and Interleukin-13 signaling” pathways, 7 were shared by AD-Longevity overlap genes. Key hit genes involved with these pathways include TNF, IL10, IL18, and IL6. These genes are also shown to be involved in Interleukin 10 signaling. Interleukin pathways are shown in figures 4A and 5A.

The second major Reactome group is “Plasma lipoprotein assembly, remodeling, and clearance” (FDR = $2.30E-04$; $p = 3.69E-06$). Genes in this pathway (Figure 4b and 5b) incorporate the following significant sub-pathways: “plasma lipoprotein assembly” (FDR = $7.82E-05$, $p = 5.15E-07$) which is a sub-pathway of “plasma lipoprotein remodeling”, “chylomicron remodeling”, “chylomicron assembly”, and “HDL remodeling.” The hit genes CEPT and APOE are present in all of these subcategories, highlighting their importance in this AD and longevity overlap dataset. Other top results included “Retinoid metabolism and transport”, which is a subset of “Metabolism of fat-soluble vitamins” and “NR1H2 and NR1H3-mediated signaling”, a subset of the “signal transduction” pathway. APOE is also a hit gene in these pathways.

255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305

Discussion

This study identified a diverse range of biochemical pathways, using the Reactome analysis of each individual set of AD, AR, and Longevity genes. We compiled and removed redundancies of the pathways into comparable groups by highlighting the hallmarks of each subset and comparing each individual gene set to the pathways involved in the overlapping (AD-AR and AD-Longevity) gene sets. Figure 6 summarizes pathways involved in each subset, which are further discussed in the subsequent sections.

AD genes

Key genes involved in the AD subset are components of mitochondrial processing of RNA, lipoprotein metabolism, and interleukin signaling (Figure 7). This aligns with the mitochondrial cascade which proposes that mitochondrial function and change rates influence AD chronology. Reactome analysis has made mitochondrial genes the top hit when associated with AD genes alone, signaling its importance and the need for more data on possible interventions. Lipoprotein metabolism and interleukin signaling will be discussed in subsequent sections.

AR genes

Key genes that are unique to the AR subset are components of DNA double-strand break (DSB) repair and cellular senescence (Figure 8). DSB can precipitate genomic rearrangements affecting multiple genes thus leading to much broader consequences when compared to other types of DNA mutations. This suggests that as humans age, DSB as well as other DNA repair mechanisms become less efficient and more-error prone (Gorbunova V et. al, 2016). Cellular Senescence is a cellular response characterized by a stable growth arrest and other phenotypic alterations that play a role in normal development, tissue homeostasis, and preventing tumor progression. It has been implicated as a major cause of the age-related disease (McHugh et. al, 2018). This suggests that further study of cellular senescence can lead to novel therapies for age-related diseases.

Longevity genes

Key genes involved in longevity are components of the PIP3-AKT and mTOR pathways (Figure 9). PIP3-AKT is a part of the insulin and IGF-1 signaling pathway which regulates FOXO (forkhead box O), a subset of a large family of transcription factors which have been shown to be involved in many cellular processes such as cell growth and survival, especially FOXO3 and FOXO1 genes (Martins et al., 2015). The mechanistic target of rapamycin (mTOR), which is also a downstream target of the insulin/PIP3/AKT pathway, is a protein kinase in a highly conserved pathway that senses nutrients and other environmental signals and coordinates several fundamental cellular responses, such as cell growth and proliferation, and has been linked to the physiological process of aging. (Saxton and Sabatini, 2017). Previous studies have shown that inhibition of mTOR enhances longevity and decreases aging and age-related disease in model organisms (Weichhart 2018). The transcription factor TP53 which encodes tumor suppressor p53 is involved in several aging-related pathways such as apoptosis and senescence and has also been shown to influence insulin/mTOR signaling which can contribute to longevity (Feng et al., 2011).

Comparing AR Pathways with Longevity Pathways

Based on our Reactome analysis, there are shared biological pathways among AR and Longevity genes, including the immune system and cytokine signaling, signal transduction, and gene expression are involved in the balance between aging and longevity. Aging also has components of impaired DNA repair, metabolism of proteins, as well as cellular senescence.

306 We have compared the pathways involved in AR and Longevity genes, which represent the
307 balance of shared pathways (Figure 10).

308

309 **AD-AR overlap genes**

310 Although the gene ontology for the AD-AR Overlap genes demonstrated involvement in a broad
311 range of biological pathways, concurrent with previous studies, some of our most significant
312 associations involve TP53, FOXO, and SUMOylation (Table 4 and Figure 11).

313 The TP53 gene provides instructions for making a prominent tumor suppressor protein called
314 tumor protein p53 which regulates DNA repair and cell division. This adds to the consistent
315 support that p53 represents a potential peripheral biomarker that could detect AD at its earliest
316 stages (Abate et al., 2020).

317

318 FOXO proteins are a subgroup of the Forkhead family of transcription factors involved in the
319 regulation of metabolism, regulation of reactive species, and regulation of cell cycle arrest and
320 apoptosis. This adds to the support that there has been increased plaque load and core plaque
321 size, commonly found in AD progression, in the cortex of mice with FOXO3 deficiency (Shuqi et
322 al., 2019).

323

324 Histopathologically, AD features insoluble aggregates of two proteins in the brain, amyloid- β
325 (A β) and tau aggregates - both of which have been linked to the small ubiquitin-like modifier
326 (SUMO). This adds to the support that early studies have indicated that the SUMO system is
327 likely altered with AD-type pathology (Lee et al., 2013).

328

329 **AD-Longevity overlap genes**

330 Significant pathways generated from the AD-Longevity overlap set include cytokine signaling in
331 the immune system and lipoprotein metabolism, which is related to the metabolism of fat-soluble
332 vitamins and NR1H2 and NR1H3-mediated signaling. (Figure 12).

333

334 Cytokines are known to play an integral role in regulating inflammatory pathways, including
335 neuroinflammation in Alzheimer's disease. A β plaques have been shown to increase levels of
336 proinflammatory cytokines IL6 and TNF alpha- among others, leading to a vicious cycle of
337 cytokine-derived inflammation and plaque accumulation (Rubio-Perez 2012). Proinflammatory
338 cytokines TNF alpha and especially IL6 have been shown to become more prevalent with age.
339 Thus genetic differences in these cytokines could serve as a potential connection to either
340 longevity or aging and inflammatory age-related diseases (Singh 2010). It has been theorized
341 that in longer-lived individuals, the polymorphisms that express lower IL6 levels would be
342 negatively correlated, but studies have had mixed results (Guiliani et al., 2018) (Di Bona D.,
343 2009), (Wei GZ, 2016). IL4 is anti-inflammatory in the brain and has been shown to potentially
344 counter the inflammatory processes in age-related diseases in mice, although detailed
345 mechanisms are not yet known (Gadani 2012). Our present study reveals the importance of the
346 interplay and balance of cytokines, especially IL4 and IL6, which would be a potential area for
347 further research.

348

349 The second category in the AD-longevity overlap genes is plasma lipoprotein metabolism.
350 Interestingly, lipoprotein metabolism was not a top result when analyzing the longevity genes
351 alone, but is significant in the overlap group. This reiterates the importance of lipoprotein
352 metabolism specifically in the context of its relation to AD. Two genes are important in this
353 pathway: Apolipoprotein E (APOE) and cholesteryl ester transfer protein (CEPT).

354

355 Polymorphisms of APOE are an established risk factor for developing AD by enhancing A β -led
356 inflammation and deterioration (Yamazaki 2019). Polymorphisms of CEPT are potential

357 candidates for risk factors for developing AD but results have been discordant. (Arias-Vásquez
358 et al., 2007). Despite being shown to increase the risk of developing AD, these genes are
359 difficult to target or change, since they are needed for normal lipid homeostasis. Further,
360 variants could be evolutionarily beneficial earlier in life, an example of antagonistic pleiotropy
361 (Tuminello and Han, 2011). Thus, future studies should emphasize the interplay between genes
362 and lifestyle throughout a person's lifetime.

363 364 **Technical advantages and limitations**

365 Gene set enrichment analysis (GSEA) is a computational method that is useful to interpret the
366 biological functions of a gene set with statistical confidence. Reactome incorporates GSEA
367 embedded with the knowledge database that covers more than 100 bioinformatics resources.
368 The Reactome outputs include statistical confidence levels with p-values and false discovery
369 rate, which raises the confidence level of evidence. The gene enrichment algorithms use a
370 score-ranked list and compare it with random rankings (Subramanian et al. 2005), which
371 provides a reasonable level of statistics with a p-value and false discovery rate. Thus, we
372 suggest that the results from this study represent the most current genetic hallmarks involved in
373 AD, aging, and longevity. In fact, this study provides a comprehensive update of the genomic
374 map of the AR genes reported nearly two decades ago (de Magalhaes and Toussaint, 2004).

375
376 However, the results from GSEA should be viewed as living knowledge, which requires updates
377 until the knowledge is saturated and complete. A potential limitation is that connections among
378 genes and annotations may be influenced by previous studies, which can be minimized by peer
379 review, systematic review, and meta-analysis. Although poor study design and controls in a
380 GWAS study may influence overall annotations, it is likely that GSEA and the review systems
381 minimize the impact of such a study. We also used a stringent condition ($p < 1.00E-05$), which is
382 backed up by the false discovery rate $< 1.00E-03$. Additionally, knowledge databases, such as
383 Reactome (<https://reactome.org/>) and KEGG (<https://www.genome.jp/kegg/>), process the data
384 rigorously with continued updates, which should reduce incorporating experimental errors.
385 Another limitation is manually-curated annotation nomenclatures, some of which may not be
386 easy to understand. For example, stress resistance to a variety of stresses (i.e., multiplex stress
387 resistance) is a component of longevity (Murakami and Johnson, 1996; Murakami, 2006; Miller
388 et al., 2017), which cannot be identified using the current annotation and thus remains to be
389 investigated.

390 391 **Future Direction**

392 In this present study, we investigated and interpreted the gene profiles of aging and longevity
393 and their association with Alzheimer's disease genes. We used the Reactome analysis which
394 provides gene set enrichment analysis to provide confidence levels for each genetic pathway.
395 Our results suggest overlapping pathways that involve TP53, FOXO, protein metabolism
396 (SUMO), cytokine balance, and lipoprotein metabolism. The genetic hallmarks identified in this
397 study provide unexpectedly broad mechanisms, suggesting a wide variety of implications in the
398 field of aging. Manually-curated annotations may need to be optimized to understand AD, aging,
399 and longevity more accurately. Further studies about environmental and lifestyle factors may
400 strengthen the knowledge about the development of Alzheimer's disease and age-related
401 comorbidities (Le et al., 2021; Li and Murakami, 2022). The studies may link aging, mid-life
402 common diseases, and Alzheimer's disease (Murakami et al., 2011; Murakami, 2013). The
403 predictive contribution of each genetic variant remains modest for LOAD (Harold et al., 2009),
404 we predict that the overviews of the gene sets, including those in this study, continue to be
405 important not only for the understanding of AD but also for patients and education. Previously
406 we have proposed to include feedback from patients in research when studying health
407 (Murakami and Halperin, 2014) and provided an example (Murakami, 2016). We incorporated

408 their feedback that there might be a more meaningful approach to AD patients than simply
409 identifying the AD genes. The discussion prompted us to explore related genes and extracted
410 the biological hallmarks shared among aging, longevity, and AD. The genetic interaction
411 networks among aging, longevity, and AD provide the extraction and translation of the gene
412 information into the hallmarks as well as are the key to developing effective treatments for AD.
413 We hope to stimulate basic science research open to patients, the community, and education.
414

415
416 **Acknowledgment**

417 This work was initiated at the Program of the Master of Science in Medical Health Sciences,
418 Touro University California. We thank all the members of the Murakami laboratory at Touro
419 University-California for the helpful discussion.

420 **Figure legends**

421

422 Figure 1. Schematic providing a breakdown of the methodology used in this study. We used
423 Reactome analysis for AD genes, AR genes, Longevity genes, overlapping AD and AR genes,
424 and overlapping AD and Longevity genes.

425

426 Figure 2. Enriched pathway analysis. The entities colored purple are hits within the positive
427 gene list. Proteins are rectangles whereas elongated hexagons are complexes. (A) Generic
428 transcription pathway. (B) TP53 Regulates the transcription of death receptors and ligands. (C)
429 SUMOylation of intracellular receptors.

430

431 Figure 3. The Reactome pathways from figure 2 converted into a functional interaction network.
432 Sub-pathways within the original pathway diagrams were extracted into the FI network as well.
433 Hit genes are displayed in a thick purple border in the FI network view for a hit pathway. (A)
434 Generic transcription pathway. (B) TP53 Regulates the transcription of death receptors and
435 ligands. (C) SUMOylation of intracellular receptors.

436

437 Figure 4. Enriched pathway analysis. The entities colored purple are hits within the positive
438 gene list. Proteins are rectangles whereas elongated hexagons are complexes. (A) Generic
439 transcription pathway. (B) TP53 Regulates the transcription of death receptors and ligands. (C)
440 SUMOylation of intracellular receptors.

441

442 Figure 5. The Reactome pathways from figure 4 converted into a functional interaction network.
443 Hit genes are displayed with a purple border. (A) FI Network for Diagram of Interleukin-4,
444 Interleukin-13, and Interleukin-10 signaling, (B) FI Network for Diagram of Plasma lipoprotein
445 assembly, remodeling, and clearance.

446

447 Figure 6. Venn diagrams of Overlapping Pathways: (A) Alzheimer's genes and Aging Related
448 genes and (B) Overlapping Alzheimer's genes and Longevity genes.

449

450 Figure 7. Diagram of Reactome Pathway Enrichment of AD Genes.

451

452 Figure 8. Diagram of Reactome Pathway Enrichment of AR Genes.

453

454 Figure 9. Diagram of Reactome Pathway Enrichment of Longevity Genes.

455

456 Figure 10. A schematic illustrating proposed genetic pathways that contribute to aging and
457 longevity.

458

459 Figure 11. Diagram of Reactome Pathway Enrichment of AD-AR Overlap Genes

460

461 Figure 12. Diagram of Reactome Pathway Enrichment of AD-Longevity Overlap Genes.

Tables

Reactome Pathway	No. of total proteins in pathway	No. of hits in pathway	p-value	FDR value	Hit gene
tRNA processing in the mitochondrion	42	19	1.11E-16	1.01E-13	<i>MT-ND6, MT-TQ, MT-ND4L, MT-ND4, MT-CO1, MT-TT, MT-TR, MT-ND2, MT-ND3, MT-ND1, MT-TH, MT-CO2, MT-TG, MT-CO3, MT-TS2, MT-ATP6, MT-ATP8, MT-RNR1, MT-CYB</i>
Plasma lipoprotein assembly, remodeling, and clearance	71	21	4.44E-16	1.34E-13	<i>LIPA, LIPC, SOAT1, CETP, APOE, A2M, ABCA1, VLDLR, LDLR, NR1H2, ABCG1, LPL, ALB, APOA1, APOA4, APOA5, NPC1, NPC2, APOC4, APOC2, APOC1</i>
rRNA processing in the mitochondrion	38	17	4.44E-16	1.34E-13	<i>MT-ND4L, MT-ND4, MT-CO1, MT-TT, MT-TR, MT-ND2, MT-ND3, MT-ND1, MT-TH, MT-CO2, MT-TG, MT-CO3, MT-TS2, MT-ATP6, MT-ATP8, MT-RNR1, MT-CYB</i>
Interleukin-4 and Interleukin-13 signaling	112	21	2.57E-12	5.80E-10	<i>ICAM1, TP53, MAOA, PIK3R1, HMOX1, CD36, IL10, IL18, IL1A, IL1B, PTGS2, ALOX5, F13A1, TNF, TGFB1, POU2F1, IL6, IL8, MMP1, MMP3, CCL2</i>
Plasma lipoprotein clearance	33	12	9.58E-11	1.73E-08	<i>LIPA, LIPC, SOAT1, APOE, VLDLR, LDLR, NR1H2, APOA1, NPC1, NPC2, APOC4, APOC1</i>
Interleukin-10 signaling	47	13	4.28E-10	6.46E-08	<i>IL1RN, ICAM1, CCR2, IL10, IL18, IL1A, IL1B, PTGS2, TNF, IL6, IL8, CCL3, CCL2</i>
Retinoid metabolism and transport	44	12	2.36E-09	3.05E-07	<i>LRAT, HSPG2, APOE, LDLR, LPL, APOA1, APOA4, LRP1, LRP2, LRP8, TTR, APOC2</i>
Metabolism of fat-soluble vitamins	48	12	6.14E-09	6.93E-07	<i>LRAT, HSPG2, APOE, LDLR, LPL, APOA1, APOA4, LRP1, LRP2, LRP8, TTR, APOC2</i>

tRNA processing	146	19	1.09E-08	1.09E-06	<i>MT-ND6, MT-TQ, MT-ND4L, MT-ND4, MT-CO1, MT-TT, MT-TR, MT-ND2, MT-ND3, MT-ND1, MT-TH, MT-CO2, MT-TG, MT-CO3, MT-TS2, MT-ATP6, MT-ATP8, MT-RNR1, MT-CYB</i>
Plasma lipoprotein remodeling	32	10	1.47E-08	1.32E-06	<i>LIPC, CETP, APOE, ABCG1, LPL, ALB, APOA1, APOA4, APOA5, APOC2</i>

TABLE 2 | Reactome pathway enrichment analysis results - GenAge (AR) genes

Reactome Pathway	No. of total proteins in pathway	No. of hits in pathway	p-value	FDR value	Hit gene
Signaling by Interleukins	452	59	1.11E-16	8.66E-15	<i>APP, ATF2, MYC, AKT1, MIF, TP53, PIK3R1, HIF1A, STAT5A, STAT5B, JUN, GRB2, CDKN1A, IKBKB, JAK2, FOS, CTF1, PTGS2, RELA, STAT3, VEGFA, IRS1, IRS2, TNF, SQSTM1, SHC1, FOXO3, FOXO1, SOCS2, UBB, HSPA9, HSPA8, TGFB1, IL2, NFKB1, NFKB2, NFKBIA, IL6, IL7, BCL2, IL7R, HMGB1, PIK3CB, LMNB1, HSP90AA1, YWHAZ, CREB1, PIK3CA, IL2RG, CDC42, MAPK9, MAPK8, PTK2B, MAPK3, PTPN11, MAPK14, S100B, SOD2, SOD1</i>
DNA Double-Strand Break Repair	149	30	1.11E-16	8.66E-15	<i>CHEK2, TP53, PRKDC, TP53BP1, XRCC6, XRCC5, ATM, ATR, FEN1, BRCA1, BRCA2, PARP1, SIRT6, PCNA, WRN, RPA1, NBN, BLM, UBB, ABL1, UBE2I, SUMO1, H2AFX, CCNA2, MAPK8, POLD1, RAD52, RAD51, ERCC4, ERCC1</i>

PIP3 activates AKT signaling	286	46	1.11E-16	8.66E-15	<i>ATF2, AKT1, TP53, PDGFB, PIK3R1, EGR1, JUN, INSR, GRB2, CDKN1A, BMI1, PPARG, EGFR, RICTOR, IRS1, IRS2, PDGFRB, PDGFRA, FOXO4, FOXO3, FOXO1, UBB, FGF23, KL, ESR1, MDM2, FGFR1, GSK3B, GSK3A, PTEN, PIK3CB, PDPK1, NRG1, CREB1, PIK3CA, HDAC2, HDAC3, HDAC1, INS, ERBB2, MAPK3, EGF, PTPN11, MTOR, PML, STUB1</i>
Intracellular signaling by second messengers	326	49	1.11E-16	8.66E-15	<i>ATF2, AKT1, PRKCD, PRKCA, TP53, PDGFB, PIK3R1, EGR1, JUN, INSR, GRB2, CDKN1A, BMI1, PPARG, EGFR, ADCY5, RICTOR, IRS1, IRS2, PDGFRB, PDGFRA, FOXO4, FOXO3, FOXO1, UBB, FGF23, KL, ESR1, MDM2, FGFR1, GSK3B, GSK3A, PTEN, PIK3CB, PDPK1, NRG1, CREB1, PIK3CA, HDAC2, HDAC3, HDAC1, INS, ERBB2, MAPK3, EGF, PTPN11, MTOR, PML, STUB1</i>
Signaling by Receptor Tyrosine Kinases	493	60	1.11E-16	8.66E-15	<i>ATF2, AKT1, PRKCD, PRKCA, PDGFB, PIK3R1, APOE, STAT5A, EGR1, STAT5B, JUND, INSR, IGF2, IGF1, PTK2, GRB2, JAK2, HRAS, FOS, NCOR1, EGFR, RICTOR, STAT3, VEGFA, CTNNB1, IRS1, IRS2, IGF1R, EP300, PDGFRB, PDGFRA, SHC1, PSEN1, UBB, FGF23, KL, BDNF, ESR1, FGFR1, FLT1, PIK3CB, HSP90AA1, PDPK1, NRG1, NGF, CREB1, PIK3CA, INS, CDC42, ERBB2, PTK2B, MAPK3, PTPN1, EGF, PTPN11, MAPK14, S100B, MTOR, BAX, STUB1</i>
FOXO-mediated transcription	66	22	1.11E-16	8.66E-15	<i>AKT1, DDIT3, TXN, PCK1, PPARGC1A, CREBBP, CDKN1A, SIRT1, SIRT3, NR3C1, STK11, EP300, FOXO4, FOXO3, FOXO1, SIN3A, YWHAZ, CAT, HDAC2, HDAC1, INS, SOD2</i>

RNA Polymerase II Transcription	1363	110	1.11E-16	8.66E-15	<i>RB1, ATF2, MT-CO1, SERPINE1, CHEK2, MYC, AKT1, TP63, MED1, AR, DDIT3, TP53, TXN, PRDX1, APOE, PCK1, PPARGC1A, CREBBP, JUN, ATM, ATR, TP73, CDKN1A, BRCA1, BMI1, PARP1, FOS, SIRT1, SIRT3, NCOR2, NCOR1, PPARG, PPARA, PCNA, HTT, EGFR, RELA, WRN, RICTOR, CDKN2B, CDKN2A, GSR, RPA1, GTF2H2, MLH1, VEGFA, CTNNB1, FAS, NR3C1, CTGF, STK11, EP300, NBN, IGFBP3, BLM, MAX, FOXO4, FOXO3, FOXO1, UBB, ABL1, TFAP2A, TGFB1, UBE2I, BDNF, ESR1, IL2, NFKB1, CDK7, IL6, SP1, CDK1, MDM2, PIN1, TCF3, GSK3B, PTEN, SUMO1, SIN3A, TBP, PDPK1, H2AFX, YWHAZ, CCNA2, CREB1, TFDP1, CAT, CEBPB, HDAC2, HDAC3, HDAC1, PPM1D, HSPD1, INS, ERBB2, E2F1, MAPK3, PTPN1, PTPN11, MAPK14, SOD2, MTOR, PML, RAD51, ERCC3, SST, ERCC2, BAX, STUB1, TAF1</i>
Generic Transcription Pathway	1234	110	1.11E-16	8.66E-15	<i>RB1, ATF2, MT-CO1, SERPINE1, CHEK2, MYC, AKT1, TP63, MED1, AR, DDIT3, TP53, TXN, PRDX1, APOE, PCK1, PPARGC1A, CREBBP, JUN, ATM, ATR, TP73, CDKN1A, BRCA1, BMI1, PARP1, FOS, SIRT1, SIRT3, NCOR2, NCOR1, PPARG, PPARA, PCNA, HTT, EGFR, RELA, WRN, RICTOR, CDKN2B, CDKN2A, GSR, RPA1, GTF2H2, MLH1, VEGFA, CTNNB1, FAS, NR3C1, CTGF, STK11, EP300, NBN, IGFBP3, BLM, MAX, FOXO4, FOXO3, FOXO1, UBB, ABL1, TFAP2A, TGFB1, UBE2I, BDNF, ESR1, IL2, NFKB1, CDK7, IL6, SP1, CDK1, MDM2, PIN1, TCF3, GSK3B, PTEN, SUMO1, SIN3A, TBP, PDPK1, H2AFX, YWHAZ, CCNA2, CREB1, TFDP1, CAT, CEBPB, HDAC2, HDAC3, HDAC1, PPM1D, HSPD1, INS, ERBB2, E2F1, MAPK3, PTPN1, PTPN11, MAPK14, SOD2, MTOR, PML, RAD51, ERCC3, SST, ERCC2, BAX, STUB1, TAF1</i>

Cellular responses to stress	554	61	1.11E-16	8.66E-15	<i>RB1, ATF2, AR, DDIT3, TP53, TXN, HIF1A, PRDX1, CREBBP, JUN, ATM, ATR, CDKN1A, BMI1, FOS, TERF1, SIRT1, TERF2, GSTP1, RELA, HSF1, RAE1, CDKN2B, CDKN2A, IFNB1, GSR, STAT3, RPA1, VEGFA, HSPA1B, HSPA1A, NR3C1, EP300, NBN, MAP3K5, EEF1A1, VCP, UBB, HSPA9, HSPA8, NFKB1, IL6, SP1, MDM2, GSK3B, LMNB1, HSP90AA1, GPX1, H2AFX, CCNA2, TFDP1, CAT, CEBPB, MAPK9, MAPK8, E2F1, MAPK3, MAPK14, SOD2, MTOR, SOD1</i>
SUMO E3 ligases SUMOylate target proteins	169	36	1.11E-16	8.66E-15	<i>AR, TP53, TP53BP1, PPARGC1A, CREBBP, TOP2A, TOP2B, BRCA1, BMI1, PARP1, NCOR2, PPARG, PPARA, PCNA, RELA, WRN, RAE1, CDKN2A, RPA1, NR3C1, EP300, HIC1, BLM, TFAP2A, UBE2I, ESR1, NFKB2, NFKBIA, MDM2, SUMO1, SIN3A, TOP1, HDAC2, HDAC1, PML, RAD52</i>

TABLE 3 | Reactome pathway enrichment analysis results - Longevity genes

Reactome Pathway	No. of Total Proteins in Pathway	No. of hits in pathway	p-value	FDR	HitGenes
mTOR signalling	41	19	1.11E-16	5.15E-14	<i>AKT1, RRAGA, RRAGC, RRAGB, RRAGD, RPTOR, LAMTOR2, LAMTOR3, RPS6, TSC2, TSC1, EIF4EBP1, RHEB, MLST8, AKT1S1, EIF4E, EIF4B, MTOR, RPS6KB1</i>
mTORC1-mediated signalling	24	16	1.11E-16	5.15E-14	<i>RRAGA, RRAGC, RRAGB, RRAGD, RPTOR, LAMTOR2, LAMTOR3, RPS6, EIF4EBP1, RHEB, MLST8, AKT1S1, EIF4E, EIF4B, MTOR, RPS6KB1</i>
Intracellular signaling by second messengers	326	34	1.74E-14	5.39E-12	<i>AKT1, PRKCA, RRAGA, RRAGC, RRAGB, RRAGD, TP53, MAPKAP1, TGFA, INSR, CDKN1A, RPTOR, PPARG, EGFR, RICTOR, CAMK4, LAMTOR2, LAMTOR3, IRS2, TSC2, FOXO4, FOXO3, FOXO1, KL, ESR1, NBEA, RHEB, FGFR1, PRR5, MLST8,</i>

					<i>PIK3CA, AKT1S1, INS, MTOR</i>
PIP3 activates AKT signaling	286	31	1.03E-13	2.39E-11	<i>AKT1, RRAGA, RRAGC, RRAGB, RRAGD, TP53, MAPKAP1, TGFA, INSR, CDKN1A, RPTOR, PPARG, EGFR, RICTOR, LAMTOR2, LAMTOR3, IRS2, TSC2, FOXO4, FOXO3, FOXO1, KL, ESR1, RHEB, FGFR1, PRR5, MLST8, PIK3CA, AKT1S1, INS, MTOR</i>
Generic Transcription Pathway	1234	66	3.56E-13	6.59E-11	<i>SERPINE1, AKT1, RUNX3, RRAGA, RRAGC, RRAGB, RRAGD, TP53, MAPKAP1, TGFA, GATA4, APOE, ATRIP, PPARGC1A, ATM, CDKN1A, MSTN, RPTOR, SREBF1, SIRT1, SIRT3, RAD51D, RARB, PPARG, SGK1, EGFR, WRN, RICTOR, WWOX, CDKN2B, GSR, MLH1, VEGFA, CAMK4, FAS, LAMTOR2, LAMTOR3, NR3C1, YY1, KCTD1, TSC2, TSC1, TBL1XR1, CSF1R, FOXO4, FOXO3, FOXO1, PLXNA4, TGFB1, ESRRG, ESR1, NFKB1, IL6, CDK6, RHEB, PRR5, EXO1, MLST8, YWHAG, H2AFX, IFNG, INS, TXNRD1, SOD2, MTOR, ERCC2</i>
Energy dependent regulation of mTOR by LKB1-AMPK	29	12	2.20E-12	3.39E-10	<i>RRAGA, RRAGC, RRAGB, RRAGD, RPTOR, LAMTOR2, LAMTOR3, TSC2, TSC1, RHEB, MLST8, MTOR</i>
RNA Polymerase II Transcription	1363	67	1.04E-11	1.29E-09	<i>SERPINE1, AKT1, RUNX3, RRAGA, RRAGC, RRAGB, RRAGD, TP53, MAPKAP1, TGFA, GATA4, APOE, ATRIP, PPARGC1A, ATM, CDKN1A, MSTN, RPTOR, SREBF1, SIRT1, SIRT3, RAD51D, RARB, PPARG, SGK1, EGFR, WRN, RICTOR, WWOX, CDKN2B, GSR, MLH1, VEGFA, CAMK4, FAS, LAMTOR2, LAMTOR3, NR3C1, YY1, KCTD1, TSC2, TSC1, TBL1XR1, CSF1R, FOXO4, FOXO3, FOXO1, PLXNA4, TGFB1, ESRRG, ESR1, NFKB1, IL6, CDK6, RHEB, PRR5, EXO1, MLST8, YWHAG, H2AFX, IFNG, POLDIP3, INS, TXNRD1, SOD2,</i>

					<i>MTOR, ERCC2</i>
TP53 Regulates Metabolic Genes	89	17	1.11E-11	1.29E-09	<i>AKT1, RRAGA, RRAGC, RRAGB, RRAGD, TP53, RPTOR, GSR, LAMTOR2, LAMTOR3, TSC2, TSC1, RHEB, MLST8, YWHAG, TXNRD1, MTOR</i>
FOXO-mediated transcription	66	15	1.73E-11	1.78E-09	<i>AKT1, PPARGC1A, CDKN1A, MSTN, SREBF1, SIRT1, SIRT3, NR3C1, FOXO4, FOXO3, FOXO1, PLXNA4, YWHAG, INS, SOD2</i>
Transcriptional Regulation by TP53	368	30	2.68E-10	2.25E-08	<i>AKT1,RRAGA,RRAGC,RRAGB,RRAGD,TP53,MAPK AP1,ATRIP,ATM,CDKN1A,RPTOR,RAD51D,SGK1, WRN,RICTOR,GSR,MLH1,FAS,LAMTOR2,LAMTOR 3,TSC2,TSC1,RHEB,PRR5,EXO1,MLST8,YWHAG,T XNRD1,MTOR,ERCC2</i>

TABLE 4 Comparison of AR and positive AD genes			
GenAge (AR) Genes	AlzGene (AD) Genes	Overlap Genes	Overlapped in AR genes (%)
307	356	41	13%

TABLE 5 Reactome pathway enrichment analysis results - AD-AR Overlap genes					
Reactome Pathway	No. of total proteins in pathway	No. of hits in pathway	p-value	FDR value	Hit gene
Generic Transcription Pathway	1234	22	4.05E-11	1.85E-08	<i>GSK3B, MT-CO1, SERPINE1, APOE, PCK1, TP63, TGFB1, UBE2I, PARP1, BDNF, CDKN2A, SOD2, ESR1, AR, IL6, SST, FAS,</i>

					<i>PIN1, PPARG, PPARA, TP53, TP73</i>
RNA Polymerase II Transcription	1363	22	2.84E-10	6.47E-08	<i>GSK3B, MT-CO1, SERPINE1, APOE, PCK1, TP63, TGFB1, UBE2I, PARP1, BDNF, CDKN2A, SOD2, ESR1, AR, IL6, SST, FAS, PIN1, PPARG, PPARA, TP53, TP73</i>
SUMOylation of intracellular receptors	30	5	1.08E-07	1.62E-05	<i>UBE2I, ESR1, AR, PPARG, PPARA</i>
TP53 Regulates Transcription of Death Receptors and Ligands	12	4	1.42E-07	1.62E-05	<i>TP63, FAS, TP53, TP73</i>
SUMO E3 ligases SUMOylate target proteins	169	8	1.98E-07	1.80E-05	<i>UBE2I, PARP1, CDKN2A, ESR1, AR, PPARG, PPARA, TP53</i>
Signaling by ERBB4	58	5	2.69E-06	1.75E-04	<i>PIK3R1, PSEN1, APOE, S100B, ESR1</i>
Interleukin-4 and Interleukin-13 signaling	112	6	3.83E-06	2.18E-04	<i>PIK3R1, PTGS2, TNF, TGFB1, IL6, TP53</i>
Apoptosis	179	7	4.36E-06	2.18E-04	<i>LMNA, TP63, CDKN2A, FAS, MAPT, TP53, TP73</i>
Nuclear signaling by ERBB4	32	4	6.83E-06	2.80E-04	<i>PSEN1, APOE, S100B, ESR1</i>
Platelet degranulation	128	6	8.16E-06	3.10E-04	<i>APP, SERPINE1, CLU, A2M, TGFB1, IGF1</i>

TABLE 6 Comparison of Longevity and AD Genes			
Longevity Genes	Positive AlzGene (AD) Genes	Overlap Genes	Overlapped in Longevity genes %
357	356	43	12%

Table 7 | Reactome pathway enrichment analysis results - Longevity and AD Overlap genes

Reactome Pathway	No. of total proteins in pathway	No. of Hits in Pathway	p-value	FDR value	Hit gene
Interleukin-4 and Interleukin-13 signaling	112	7	7.64E-08	2.32E-05	<i>TNF, HMOX1, IL10, TGFB1, IL18, IL6, TP53</i>
Plasma lipoprotein assembly	19	4	5.15E-07	7.82E-05	<i>APOE, APOA1, APOA4, APOC1</i>
Plasma lipoprotein assembly, remodeling, and clearance	71	5	3.69E-06	2.30E-04	<i>CETP, APOE, APOA1, APOA4, APOC1</i>
Plasma lipoprotein remodeling	32	4	4.02E-06	2.30E-04	<i>CETP, APOE, APOA1, APOA4</i>
Chylomicron remodeling	10	3	5.35E-06	2.30E-04	<i>APOE, APOA1, APOA4</i>
Chylomicron assembly	10	3	5.35E-06	2.30E-04	<i>APOE, APOA1, APOA4</i>
HDL remodeling	10	3	5.35E-06	2.30E-04	<i>CETP, APOE, APOA1</i>
Signaling by Interleukins	452	9	1.20E-05	4.57E-04	<i>AGER, TNF, HMOX1, IL10, TGFB1, IL18, SOD2, IL6, TP53</i>
Retinoid metabolism and transport	44	4	1.40E-05	4.61E-04	<i>TTR, APOE, APOA1, APOA4</i>
Interleukin-10 signaling	47	4	1.80E-05	5.29E-04	<i>TNF, IL10, IL18, IL6</i>

References

Abate G, Frisoni GB, Bourdon JC, Piccirella S, Memo M, Uberti D. The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer's disease. *Alzheimers Res Ther.* 2020 12(1):160. doi: 10.1186/s13195-020-00732-0. PMID: 33272326; PMCID: PMC7712978.

Alzheimer's Association (2015). Alzheimer's disease facts and figures. *Alzheimer's Dement.* 11, 332–384. doi: 10.1016/j.jalz.2015.02.003

Arias-Vásquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, van Duijn CM. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. *Neurogenetics.* 2007 8(3):189-93. doi: 10.1007/s10048-007-0089-x. PMID: 17503098.

Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., and Tanzi, R. E. (2007). Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat. Genet.* 39, 17–23. doi: 10.1038/ng1934

Budovsky A, Craig T, Wang J, Tacutu R, Csordas A, Lourenço J, Fraifeld VE, de Magalhães JP. LongevityMap: a database of human genetic variants associated with longevity. *Trends Genet.* 2013 Oct;29(10):559-60. doi: 10.1016/j.tig.2013.08.003. Epub 2013 Aug 30. PMID: 23998809.

Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. *Am J Hum Genet.* 1999 65(3):664-70. doi: 10.1086/302553. PMID: 10441572; PMCID: PMC1377972.

Christensen K, Johnson TE, Vaupel JW. The quest for genetic determinants of human longevity: challenges and insights. *Nat Rev Genet.* 7(6):436-48. doi: 10.1038/nrg1871. PMID: 16708071; PMCID: PMC2726954.

de Magalhaes JP, Curado J, Church GM. Meta-analysis of age-related gene expression profiles identifies common signatures of aging. *Bioinformatics.* 2009 25(7):875-81. doi: 10.1093/bioinformatics/btp073. Epub 2009 Feb 2. PMID: 19189975; PMCID: PMC2732303.

de Magalhaes JP, Toussaint O. GenAge: a genomic and proteomic network map of human ageing. *FEBS Lett.* 2004 571(1-3):243-7. doi: 10.1016/j.febslet.2004.07.006. PMID: 15280050.

Di Bona D, Vasto S, Capurso C, Christiansen L, Deiana L, Franceschi C, Hurme M, Mocchegiani E, Rea M, Lio D, Candore G, Caruso C. Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. *Ageing Res Rev.* 2009 8(1):36-42. doi: 10.1016/j.arr.2008.09.001. Epub 2008 Sep 27. PMID: 18930842.

Du S, Maneix L, Zhang Q, Wan YW, Zheng H. The role of FOXO3 transcription factor in Alzheimer's disease pathology, *Innovation in Aging, Volume 3, Issue Supplement_1, November 2019, Pages S842–S843, <https://doi.org/10.1093/geroni/igz038.3102>*

Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Viteri G, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. The Reactome

Pathway Knowledgebase. *Nucleic Acids Res.* 2018 46(D1):D649-D655. doi: 10.1093/nar/gkx1132. PMID: 29145629; PMCID: PMC5753187.

Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA.* 1997 278(16):1349-56. PMID: 9343467.

Feng Z, Lin M, Wu R. The Regulation of Aging and Longevity: A New and Complex Role of p53. *Genes Cancer.* 2011 2(4):443-52. doi: 10.1177/1947601911410223. PMID: 21779512; PMCID: PMC3135645.

Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. *J Immunol.* 2012 189(9):4213-9. doi: 10.4049/jimmunol.1202246. PMID: 23087426; PMCID: PMC3481177.

Giuliani C, Garagnani P, Franceschi C. Genetics of Human Longevity Within an Eco-Evolutionary Nature-Nurture Framework. *Circ Res.* 2018 123(7):745-772. doi: 10.1161/CIRCRESAHA.118.312562. PMID: 30355083.

Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature.* 1991 349(6311):704-6. doi: 10.1038/349704a0. PMID: 1671712.

Gorbunova V, Seluanov A. DNA double strand break repair, aging and the chromatin connection. *Mutat Res.* 2016 788:2-6. doi: 10.1016/j.mrfmmm.2016.02.004. PMID: 26923716; PMCID: PMC4887314.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet.* 2009 41(10):1088-93. doi: 10.1038/ng.440. PMID: 19734902; PMCID: PMC2845877.

Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. The reactome pathway knowledgebase. *Nucleic acids research.* 2020 48(D1) D498-D503. doi: 10.1093/nar/gkz1031. PubMed PMID: 31691815. PubMed Central PMCID: PMC7145712.

Le D, Brown L, Malik K, Murakami S. Two Opposing Functions of Angiotensin-Converting Enzyme (ACE) That Links Hypertension, Dementia, and Aging. *Int J Mol Sci.* 2021 22(24):13178. doi: 10.3390/ijms222413178. PMID: 34947975; PMCID: PMC8707689.

Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P. SUMO and Alzheimer's disease. *Neuromolecular Med.* 2013 15(4):720-736. doi:10.1007/s12017-013-8257-7

Li L, Murakami S. Artificial intelligence-assisted meta-analysis of the frequency of ACE I/D polymorphisms in centenarians and other long-lived individuals medRxiv 2022.12.10.22283306; doi: <https://doi.org/10.1101/2022.12.10.22283306>

Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mack D, McGuire LC. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥ 65 years. *Alzheimers Dement*. 2019 15(1):17-24. doi: 10.1016/j.jalz.2018.06.3063. PMID: 30243772; PMCID: PMC6333531.

Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. *Aging Cell*. 2016 15(2):196-207. doi: 10.1111/ace.12427. PMID: 26643314; PMCID: PMC4783344.

McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. *J Cell Biol*. 2018 217(1):65-77. doi: 10.1083/jcb.201708092. PMID: 29114066; PMCID: PMC5748990.

Milacic, M., Haw, R., Rothfels, K., Wu, G., Croft, D., Hermjakob, H., et al. (2012). Annotating cancer variants and anti-cancer therapeutics in reactome. *Cancers (Basel)*. 4, 1180–1211. doi: 10.3390/cancers4041180

Miller BF, Seals DR, Hamilton KL. A viewpoint on considering physiological principles to study stress resistance and resilience with aging. *Ageing Res Rev*. 2017 38:1-5. doi: 10.1016/j.arr.2017.06.004. PMID: 28676286.

Mooser V, Helbecque N, Miklossy J, Marcovina SM, Nicod P, Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease. *Ann Intern Med*. 2000 132(7):533-7. doi: 10.7326/0003-4819-132-7-200004040-00004. PMID: 10744589.

Murakami S. Stress resistance in long-lived mouse models. *Exp Gerontol*. 2006 Oct;41(10):1014-9. doi: 10.1016/j.exger.2006.06.061. PMID: 16962277.

Murakami S. Editorial: Biology of Cognitive Aging: Model Systems, Technologies, and Beyond. *Front Genet*. 2016 6:366. doi: 10.3389/fgene.2015.00366. PMID: 26793238; PMCID: PMC4709966.

Murakami, S. Age-dependent modulation of learning and memory in *C. elegans*. In Menzel R and Benjamin P.R. (Eds.) *Invertebrate Learning and Memory; Handbook of Behavioral Neuroscience*. Elsevier/Academic Press. 2013 Ch.12, Pages 140-150. doi: <https://doi.org/10.1002/9781118148143.ch25>

Murakami, S., Cabana, K., Anderson, D. Current advances in the study of oxidative stress and age-related memory impairment in *C. elegans*. In Farooqui, T. Farooqui, A. (Ed.) *Molecular aspects of oxidative stress on cell signaling in vertebrates and invertebrates*, John Wiley & Sons, Hoboken, NJ. 2011 Ch 25, Pages 347-360. doi: <https://doi.org/10.1016/B978-0-12-415823-8.00012-5>

Murakami S, Halperin AS. Alzheimer's patient feedback to complement research using model systems for cognitive aging and dementia. *Front Genet*. 2014 5:269. doi: 10.3389/fgene.2014.00269. PMID: 25147560; PMCID: PMC4123719.

Murakami S, Johnson TE. A genetic pathway conferring life extension and resistance to UV stress in *Caenorhabditis elegans*. *Genetics*. 1996 143(3):1207-18. doi: 10.1093/genetics/143.3.1207. PMID: 8807294; PMCID: PMC1207391.

Olgati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D., and Serretti, A. (2011). Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. *Int. J. Alzheimer's Dis.* 2011:832379. doi: 10.4061/2011/832379

Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature.* 1995 376(6543):775-8. doi: 10.1038/376775a0. PMID: 7651536.

Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. *ScientificWorldJournal.* 2012;2012:756357. doi: 10.1100/2012/756357. PMID: 22566778; PMCID: PMC3330269.

Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 43, 1467–1467. doi: 10.1212/WNL.43.8.1467

Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell.* 2017 Mar 9;168(6):960-976. doi: 10.1016/j.cell.2017.02.004. PMID: 28283069; PMCID: PMC5394987.

Sebastiani P, Gurinovich A, Nygaard M, Sasaki T, Sweigart B, Bae H, Andersen SL, Villa F, Atzmon G, Christensen K, Arai Y, Barzilai N, Puca A, Christiansen L, Hirose N, Perls TT. APOE Alleles and Extreme Human Longevity. *J Gerontol A Biol Sci Med Sci.* 2019 74(1):44-51. doi: 10.1093/gerona/gly174. PMID: 30060062; PMCID: PMC6298189.

Sherva S, Kwall NW. Genetics of Alzheimer disease. In Wilterdink JL (Deputy Ed), 2022 Retrieved January 6, 2023 <https://www-uptodate-com.eu1.proxy.openathens.net>

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005 102(43):15545-50. doi: 10.1073/pnas.0506580102. PMID: 16199517; PMCID: PMC1239896.

Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature.* 1995 375(6534):754-60. doi: 10.1038/375754a0. PMID: 7596406.

Singh T, Newman AB. Inflammatory markers in population studies of aging. *Ageing Res Rev.* 2011 10(3):319-29. doi: 10.1016/j.arr.2010.11.002. PMID: 21145432; PMCID: PMC3098911.

Tacutu R, Thornton D, Johnson E, Budovsky A, Barardo D, Craig T, Diana E, Lehmann G, Toren D, Wang J, Fraiefeld VE, de Magalhães JP. Human Ageing Genomic Resources: new and updated databases. *Nucleic Acids Res.* 2018 ;46(D1):D1083-D1090. doi: 10.1093/nar/gkx1042. PMID: 29121237; PMCID: PMC5753192.

Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. Meta Analysis of Human AlzGene Database: Benefits and Limitations of Using *C. elegans* for the Study of Alzheimer's Disease and Co-morbid Conditions. *Front Genet.* 2017 8:55. doi: 10.3389/fgene.2017.00055. PMID: 28553317; PMCID: PMC5427079.

Vastrik I, D'Eustachio P, Schmidt E, Gopinath G, Croft D, de Bono B, Gillespie M, Jassal B, Lewis S, Matthews L, Wu G, Birney E, Stein L. Reactome: a knowledge base of biologic pathways and processes. *Genome Biol.* 2007 8:R39. doi: 10.1186/gb-2007-8-3-r39

Wei GZ, Wang F, Zhao YG, Li SS, Shi ML, Gao K, Luo Y, Tang WR. Association of longevity with TNF- α G308A and IL-6 G174C polymorphic inflammatory biomarkers in Caucasians: a meta-analysis. *Z Gerontol Geriatr.* 2016 49(8):706-713. English. doi: 10.1007/s00391-015-0992-y. PMID: 26754162.

Weichhart T. mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review. *Gerontology.* 2018 64(2):127-134. doi: 10.1159/000484629. PMID: 29190625; PMCID: PMC6089343.

Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox DC, Rodriguez B, Curb JD. FOXO3A genotype is strongly associated with human longevity. *Proc Natl Acad Sci U S A.* 2008 105(37):13987-92. doi: 10.1073/pnas.0801030105. PMID: 18765803; PMCID: PMC2544566.

Wu G, Haw R. Functional Interaction Network Construction and Analysis for Disease Discovery. *Methods Mol Biol.* 2017 1558:235-253. doi: 10.1007/978-1-4939-6783-4_11. PMID: 28150241.

Figures

Figure 1




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12

